Search clinical trials for: Checkpoint inhibitor (CPI) such as Pembrolizumab

Total 1598 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
Eli Lilly and Company; Merck Sharp & Dohme LLC

Completed

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Pancreatic Cancer

United States
AstraZeneca
Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo

Recruiting

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (DG-03)

Gastric Cancer

China, Spain, Korea, Republic of, Canada, Italy, Poland, Japan, United Kingdom, Brazil, Taiwan, United States, Germany, Netherlands, Russian Federation
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Stage I Uterine Corpus Cancer AJCC v8 | Stage II Uterine Corpus Cancer AJCC v8

United States, Puerto Rico
Bristol-Myers Squibb
AbbVie

Completed

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)

Multiple Myeloma

Canada, United States, Israel, Czechia, Switzerland, Greece, Denmark, Portugal, Italy, Germany, Austria, Norway, Puerto Rico, Spain, Sweden, Turkey
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Laura M. Spring, MD
Merck Sharp & Dohme LLC; Translational Breast Cancer Research Consortium; Breast...

Recruiting

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Triple Negative Breast Cancer | Hormone Receptor Positive (HR+), HER2-negative Breast Cancer | Biopsy-proven, Positive Lymph Node(s)

United States
Roswell Park Cancer Institute
AIM ImmunoTech Inc.

Completed

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple -Negative Breast Cancer | Anatomic Stage IV Breast Cancer AJCC

United States
National Cancer Institute (NCI)

Active, not recruiting

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Metastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...

United States, Canada, Ireland
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Not yet recruiting

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer (PRIAM)

Urologic Neoplasms | Urogenital Neoplasms | Penile Cancer | Male Urogenital Diseases | Penile Squamous Cell Carcinoma | Locally Advanced Penile Carcinoma
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

Ovarian Carcinoma | High-grade Serous Ovarian Carcinoma

Korea, Republic of, Spain, Poland, United States, Belgium, Canada, Chile, Israel, Italy, Singapore, Taiwan
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Esophageal Squamous Cell Carcinoma (ESCC) | Gastroesophageal Junction Carcinoma (GEJC) | Esophageal Adenocarcinoma (EAC)

China, Canada, United States, Argentina, Belgium, Brazil, Chile, Czechia, Denmark, Estonia, France, Germany, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Mexico, Peru, Philippines, Portugal, Romania, Russian Federation and more
Beijing Tongren Hospital

Recruiting

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy | Pembrolizumab

China
National Cancer Institute (NCI)

Suspended

A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Melanoma

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Triple Negative Breast Cancer (TNBC)
Sumitomo Pharma America, Inc.

Completed

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Cancer

Canada, United States
Mayo Clinic

Recruiting

A Study of FRaDCs for Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian... and other conditions

United States
ETOP IBCSG Partners Foundation
Merck Sharp & Dohme LLC; Frontier Science Foundation, Hellas

Completed

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma (PROMISE-meso)

Pleural Mesothelioma Malignant Advanced

United Kingdom, Switzerland, Spain
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Lymphocyte-Rich Classical Hodgkin Lymphoma | Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma | Recurrent Mixed Cellularity Classical Hodgkin Lymphoma | Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma | Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma | Refractory Mixed... and other conditions

United States
Wake Forest University Health Sciences

Not yet recruiting

Intramedullary Calcium Sulfate Antibiotic Depot

Tibial Fractures | Open tíbia Fracture | Osteomyelitis Tibia

United States
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
NuCana plc

Recruiting

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Advanced Cancer | Head and Neck Squamous Cell Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Neoplasm Malignant | Pleural... and other conditions

United Kingdom
Tianhong Li
National Cancer Institute (NCI); LabyRx Immunologic Therapeutics

Recruiting

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Adenocarcinoma | Advanced Adenocarcinoma | Recurrent Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditions

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Advanced Malignant Skin Neoplasm | Metastatic Malignant Skin Neoplasm

United States
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Hoffmann-La Roche

Active, not recruiting

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung)

Carcinoma, Non-Small-Cell Lung

United States, Spain, Korea, Republic of, France, Israel, Taiwan, Australia, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III... and other conditions

United States
Trishula Therapeutics, Inc.
AbbVie

Completed

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Solid Tumor, Adult

United States, Korea, Republic of
Immodulon Therapeutics Ltd

Terminated

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (MODULATE)

Metastatic Cancer

France, United Kingdom
Baylor Breast Care Center

Recruiting

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE)

Breast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer Invasive

United States
Vall d'Hebron Institute of Oncology

Recruiting

Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform (PORTRAIT)

Triple Negative Breast Cancer

Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC (NeoADAPT)

Triple Negative Breast Cancer

United States
Toray Industries, Inc

Recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Cholangiocarcinoma | Bladder Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer | Palpable Subcutaneous Malignant Lesions

United States, France
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

Poland, Romania, Ukraine, Chile, Canada, United States, Argentina, China, Czechia, Estonia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Norway, Peru, Russian Federation, Spain, Thailand, Turkey, United...
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Advanced Solid Tumors

China, United States, Australia, Canada, Chile, Israel, Japan, Korea, Republic of, Panama, Poland, Spain, Switzerland, Turkey, New Zealand, Taiwan, Denmark
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Hodgkin Lymphoma

United States, Brazil, Colombia, Czechia, France, Germany, Greece, Guatemala, Italy, Korea, Republic of, Mexico, Netherlands, Slovakia, South Africa, Spain, United Kingdom
Medical University of South Carolina

Recruiting

Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
University of Chicago
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Lymphoma | Lymphoma, B-Cell | B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Daniel Benjamin
National Center for Advancing Translational Sciences (NCATS); Biomedical Advanced...

Completed

Immune Modulators for Treating COVID-19 (ACTIV-1 IM)

Covid19

United States, Brazil, Argentina, Mexico, Peru
Hoffmann-La Roche

Recruiting

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)

Cancer

United States, France, Korea, Republic of, Taiwan, Japan, Spain, Belgium, Brazil, Czechia, Romania, Thailand, Australia, Bulgaria, Canada, Chile, Denmark, Germany, Greece, Guatemala, Hungary, Latvia, Mexico, Norway, Poland, Slovakia, Swit... and more
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC; Prometheus Laboratories

Active, not recruiting

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Kidney Cancer

United States
Amgen

Recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Advanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C Mutation

United States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
Baylor College of Medicine
National Cancer Institute (NCI); The Methodist Hospital Research Institute; Center... and other collaborators

Active, not recruiting

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (GRAIN)

Neuroblastoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Nonsmall Cell Lung Cancer | Performance Status

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, New Zealand
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Non-Small Cell Lung Carcinoma

Search clinical trials for: Checkpoint inhibitor (CPI) such as Pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations